Trials / Completed
CompletedNCT00062686
GW572016 For Treatment Of Refractory Metastatic Breast Cancer
An Open-Label, Multicenter, Single Arm Phase II Study of Oral GW572016 as Single Agent Therapy in Subjects With Advanced or Metastatic Breast Cancer Who Have Progressed While Receiving HERCEPTIN-Containing Regimens
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 200 (planned)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study was designed to determine the efficacy of an oral dual kinase inhibitor for the treatment of metastatic breast cancer tumors that are known to overexpress ErbB2 in a refractory patient population.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GW572016 |
Timeline
- Start date
- 2003-11-01
- Primary completion
- 2005-02-01
- Completion
- 2005-02-01
- First posted
- 2003-06-12
- Last updated
- 2015-04-15
Locations
7 sites across 4 countries: Argentina, France, Germany, United Kingdom
Source: ClinicalTrials.gov record NCT00062686. Inclusion in this directory is not an endorsement.